Wu S, Chiang C. Distinct Role of CD11b+Ly6G-Ly6C- Myeloid-Derived Cells on the Progression of the Primary Tumor and Therapy-Associated Recurrent Brain Tumor. Cells. 2019;9: pubmed publisher

Zhang T, Chai J, Chi L. Induction Of XLF And 53BP1 Expression Is Associated With Temozolomide Resistance In Glioblastoma Cells. Onco Targets Ther. 2019;12:10139-10151 pubmed publisher

Chen K, Chen P, Ho K, Shih C, Chou C, Cheng C, et al. IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway. PLoS ONE. 2019;14:e0225913 pubmed publisher

Silva V, Rosa M, Tansini A, Martinho O, Tanuri A, Evangelista A, et al. Semi-Synthetic Ingenol Derivative from Euphorbia tirucalli Inhibits Protein Kinase C Isotypes and Promotes Autophagy and S-phase Arrest on Glioma Cell Lines. Molecules. 2019;24: pubmed publisher

Kim H, Lee B, Jeon J, Kim D, Kang S, Shim J, et al. Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres. Biomolecules. 2019;9: pubmed publisher

Wen Y, Wu A, Bamodu O, Wei L, Lin C, Yen Y, et al. A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis. Cancers (Basel). 2019;11: pubmed publisher

Hong J, Kim J, Kim H, Lee W, Hwang Y. SB365, Pulsatilla Saponin D Induces Caspase-Independent Cell Death and Augments the Anticancer Effect of Temozolomide in Glioblastoma Multiforme Cells. Molecules. 2019;24: pubmed publisher

Memarzadeh K, Savage D, Bean A. Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition. Cancer Biol Ther. 2019;20:1416-1429 pubmed publisher

Bittencourt L, Negreiros Lima G, Sousa L, Silva A, Souza I, Ribeiro R, et al. G3BP1 knockdown sensitizes U87 glioblastoma cell line to Bortezomib by inhibiting stress granules assembly and potentializing apoptosis. J Neurooncol. 2019;144:463-473 pubmed publisher

Rusu P, Shao C, Neuerburg A, Acikgöz A, Wu Y, Zou P, et al. GPD1 Specifically Marks Dormant Glioma Stem Cells with a Distinct Metabolic Profile. Cell Stem Cell. 2019;25:241-257.e8 pubmed publisher

Vengoji R, Macha M, Nimmakayala R, Rachagani S, Siddiqui J, Mallya K, et al. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Exp Clin Cancer Res. 2019;38:266 pubmed publisher

Dréan A, Lemaire N, Bouchoux G, Goldwirt L, Canney M, Goli L, et al. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma. J Neurooncol. 2019;: pubmed publisher

Mihajluk K, Simms C, Reay M, Madureira P, Howarth A, Murray P, et al. IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas. Cancer Lett. 2019;458:29-38 pubmed publisher

Liu Z, Jiang X, Gao L, Liu X, Li J, Huang X, et al. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. World Neurosurg. 2019;: pubmed publisher

Skaga E, Skaga I, Grieg Z, Sandberg C, Langmoen I, Vik Mo E. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. J Cancer Res Clin Oncol. 2019;145:1495-1507 pubmed publisher

Kucab J, Zou X, Morganella S, Joel M, Nanda A, Nagy E, et al. A Compendium of Mutational Signatures of Environmental Agents. Cell. 2019;177:821-836.e16 pubmed publisher

Mazor G, Levin L, Picard D, Ahmadov U, Caren H, Borkhardt A, et al. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death Dis. 2019;10:246 pubmed publisher

Karachi A, Yang C, Dastmalchi F, Sayour E, Huang J, Azari H, et al. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol. 2019;21:730-741 pubmed publisher

Lundy D, Lee K, Peng I, Hsu C, Lin J, Chen K, et al. Inducing a Transient Increase in Blood-Brain Barrier Permeability for Improved Liposomal Drug Therapy of Glioblastoma Multiforme. ACS Nano. 2019;13:97-113 pubmed publisher

Pavlyukov M, Yu H, Bastola S, Minata M, Shender V, Lee Y, et al. Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma Via Intercellular Transfer of Splicing Factors. Cancer Cell. 2018;34:119-135.e10 pubmed publisher

Hegge B, Sjøttem E, Mikkola I. Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress. BMC Cancer. 2018;18:496 pubmed publisher

Dréan A, Rosenberg S, Lejeune F, Goli L, Nadaradjane A, Guehennec J, et al. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma. J Neurooncol. 2018;138:479-486 pubmed publisher

Witusik Perkowska M, Zakrzewska M, Sikorska B, Papierz W, Jaskolski D, Szemraj J, et al. Glioblastoma-derived cells in vitro unveil the spectrum of drug resistance capability - comparative study of tumour chemosensitivity in different culture systems. Biosci Rep. 2017;37: pubmed publisher

Sampson V, Vetter N, Kamara D, Collier A, Gresh R, Kolb E. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways. PLoS ONE. 2015;10:e0142704 pubmed publisher

Banelli B, Carra E, Barbieri F, Würth R, Parodi F, Pattarozzi A, et al. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle. 2015;14:3418-29 pubmed publisher

Bison S, Haeck J, Bol K, Koelewijn S, Groen H, Melis M, et al. Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies. EJNMMI Res. 2015;5:62 pubmed publisher

Guan D, Chen H, Liao S, Zhao T. Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol?resistant glioma cells via inhibition of glucose metabolism. Mol Med Rep. 2015;12:7705-11 pubmed publisher

Barciszewska A, Gurda D, Głodowicz P, Nowak S, Naskręt Barciszewska M. A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells. PLoS ONE. 2015;10:e0136669 pubmed publisher

Stepanenko A, Dmitrenko V. Pitfalls of the MTT assay: Direct and off-target effects of inhibitors can result in over/underestimation of cell viability. Gene. 2015;574:193-203 pubmed publisher

Dolman M, Poon E, Ebus M, den Hartog I, van Noesel C, Jamin Y, et al. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clin Cancer Res. 2015;21:5100-9 pubmed publisher

Mahgoub T, Eustace A, Collins D, Walsh N, O Donovan N, Crown J. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma. Int J Oncol. 2015;47:900-8 pubmed publisher

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, et al. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Cancer Lett. 2015;367:58-68 pubmed publisher

Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi M, et al. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells. Clin Cancer Res. 2015;21:5324-37 pubmed publisher

Yim N, Jung Y, Kim A, Kim T, Ma J. Induction of apoptotic cell death by betulin in multidrug-resistant human renal carcinoma cells. Oncol Rep. 2015;34:1058-64 pubmed publisher

Tian T, Li A, Lu H, Luo R, Zhang M, Li Z. TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells. Biochem Biophys Res Commun. 2015;463:638-43 pubmed publisher

Cioccoloni G, Bonmassar L, Pagani E, Caporali S, Fuggetta M, Bonmassar E, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015;47:764-72 pubmed publisher

Bhuvanalakshmi G, Arfuso F, Millward M, Dharmarajan A, Warrier S. Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties. PLoS ONE. 2015;10:e0127517 pubmed publisher

Stojković S, Podolski Renić A, Dinić J, Stanković T, Banković J, Hadžić S, et al. Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin. Exp Cell Res. 2015;335:248-57 pubmed publisher

Qin L, Jia P, Zhang Z, Zhang S. ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis. J Exp Clin Cancer Res. 2015;34:57 pubmed publisher

Gleize V, Alentorn A, Connen de Kérillis L, Labussière M, Nadaradjane A, Mundwiller E, et al. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. Ann Neurol. 2015;78:355-74 pubmed publisher

Piskareva O, Harvey H, Nolan J, Conlon R, Alcock L, Buckley P, et al. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. Cancer Lett. 2015;364:142-55 pubmed publisher

Wei J, Qi X, Zhan Q, Zhou D, Yan Q, Wang Y, et al. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression. Biomed Pharmacother. 2015;71:112-8 pubmed publisher

Bryukhovetskiy I, Bryukhovetsky A, Khotimchenko Y, Mischenko P, Tolok E, Khotimchenko R. Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma. Mol Med Rep. 2015;12:2828-34 pubmed publisher

Linz U, Hupert M, Santiago Schübel B, Wien S, Stab J, Wagner S. Transport of treosulfan and temozolomide across an in-vitro blood-brain barrier model. Anticancer Drugs. 2015;26:728-36 pubmed publisher

Chong D, Toh X, Ho I, Sia K, Newman J, Yulyana Y, et al. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer. 2015;15:255 pubmed publisher

Liao H, Bai Y, Qiu S, Zheng L, Huang L, Liu T, et al. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget. 2015;6:8914-28 pubmed

Li M, Chao L, Wu J, Xu H, Shen S, Chen S, et al. Pygo2 siRNA Inhibit the Growth and Increase Apoptosis of U251 Cell by Suppressing Histone H3K4 Trimethylation. J Mol Neurosci. 2015;56:949-955 pubmed publisher

Sesen J, Dahan P, Scotland S, Saland E, Dang V, Lemarie A, et al. Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. PLoS ONE. 2015;10:e0123721 pubmed publisher

Tabouret E, Tchoghandjian A, Denicolaï E, Delfino C, Metellus P, Graillon T, et al. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. Oncotarget. 2015;6:11664-75 pubmed

Krishnamurthy N, Liu L, Xiong X, Zhang J, Montano M. Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells. Cancer Biol Ther. 2015;16:518-27 pubmed publisher

Chen L, Rousseau R, Middleton S, Nichols G, Newell D, Lunec J, et al. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015;6:10207-21 pubmed

Mansour N, Bernal G, Wu L, Crawley C, Cahill K, Voce D, et al. Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide. Cancer Res. 2015;75:2039-48 pubmed publisher

Briest F, Berg E, Grass I, Freitag H, Kaemmerer D, Lewens F, et al. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors. Oncotarget. 2015;6:8185-99 pubmed

Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, et al. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochem Pharmacol. 2015;95:16-27 pubmed publisher

Goldwirt L, Beccaria K, Carpentier A, Idbaih A, Schmitt C, Levasseur C, et al. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide. J Neurooncol. 2015;122:273-81 pubmed publisher

Erice O, Smith M, White R, Goicoechea I, Barriuso J, Jones C, et al. MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. Mol Cancer Ther. 2015;14:1236-46 pubmed publisher

Fiedler T, Strauss M, Hering S, Redanz U, William D, Rosche Y, et al. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. Cancer Biol Ther. 2015;16:1047-55 pubmed publisher

Pojo M, Gonçalves C, Xavier Magalhães A, Oliveira A, Gonçalves T, Correia S, et al. A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. Oncotarget. 2015;6:7657-74 pubmed

Lin T, Lee C, Chen K, Lin C, Shih C. Inhibition of RNA transportation induces glioma cell apoptosis via downregulation of RanGAP1 expression. Chem Biol Interact. 2015;232:49-57 pubmed publisher

Reilly E, Phillips A, Buchanan F, Kingsbury G, Zhang Y, Meulbroek J, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015;14:1141-51 pubmed publisher

Filippi Chiela E, Bueno E Silva M, Thomé M, Lenz G. Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage. Autophagy. 2015;11:1099-113 pubmed publisher

Ma L, Liu J, Zhang X, Qi J, Yu W, Gu Y. p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ. Med Oncol. 2015;32:69 pubmed publisher

Hosein A, Lim Y, Day B, Stringer B, Rose S, Head R, et al. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. J Neurooncol. 2015;122:263-71 pubmed publisher

Pokorny J, Calligaris D, Gupta S, Iyekegbe D, Mueller D, Bakken K, et al. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clin Cancer Res. 2015;21:1916-24 pubmed publisher

Majuelos Melguizo J, Rodríguez M, López Jiménez L, Rodríguez Vargas J, Martí Martín Consuegra J, Serrano Sáenz S, et al. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma. Oncotarget. 2015;6:4790-803 pubmed

Zanotto Filho A, Braganhol E, Klafke K, Figueiró F, Terra S, Paludo F, et al. Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. Cancer Lett. 2015;358:220-31 pubmed publisher

Karpel Massler G, Kast R, Westhoff M, Dwucet A, Welscher N, Nonnenmacher L, et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. J Neurooncol. 2015;122:21-33 pubmed publisher

Liu Q, Xu X, Zhao M, Wei Z, Li X, Zhang X, et al. Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway. Mol Cancer Ther. 2015;14:355-63 pubmed publisher

Chakraborty S, Li L, Puliyappadamba V, Guo G, Hatanpaa K, Mickey B, et al. Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. Nat Commun. 2014;5:5811 pubmed publisher

Chamberlain M. Glioblastoma in the elderly. Cancer Treat Res. 2015;163:159-70 pubmed publisher

Canello T, Ovadia H, Refael M, Zrihan D, Siegal T, Lavon I. Antineoplastic effect of decoy oligonucleotide derived from MGMT enhancer. PLoS ONE. 2014;9:e113854 pubmed publisher

Piccirillo S, Spiteri I, Sottoriva A, Touloumis A, Ber S, Price S, et al. Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone. Cancer Res. 2015;75:194-202 pubmed publisher

Croucher J, Iyer R, Li N, Molteni V, Loren J, Gordon W, et al. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts. Cancer Chemother Pharmacol. 2015;75:131-41 pubmed publisher

Breshears J, Ivan M, Cotter J, Bollen A, Theodosopoulos P, Berger M. Primary glioblastoma of the trigeminal nerve root entry zone: case report. J Neurosurg. 2015;122:78-81 pubmed publisher

Jung T, Lee J, Kim D, Park H, Kim C, Ra Y, et al. Pediatric supratentorial high-grade glioma: multicenter retrospective observational study of the Korean Society for Pediatric Neuro-Oncology. J Neurooncol. 2015;121:413-9 pubmed publisher

Yao C, Han T, Shih P, Yi T, Lai I, Chang K, et al. Elimination of cancer stem-like side population in human glioblastoma cells accompanied with stemness gene suppression by Korean herbal recipe MSC500. Integr Cancer Ther. 2014;13:541-54 pubmed publisher

Chai K, Wang C, Liaw H, Fang K, Yang C, Tzeng S. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide. Oncotarget. 2014;5:10901-15 pubmed

Park I, Mukherjee J, Ito M, Chaumeil M, Jalbert L, Gaensler K, et al. Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. Cancer Res. 2014;74:7115-24 pubmed publisher

Koschny R, Boehm C, Sprick M, Haas T, Holland H, Xu L, et al. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex. J Neuropathol Exp Neurol. 2014;73:1034-46 pubmed publisher

Yang N, Yan T, Zhu H, Liang X, Leiss L, Sakariassen P, et al. A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma. J Transl Med. 2014;12:278 pubmed publisher

Zhang J, Hummersone M, Matthews C, Stevens M, Bradshaw T. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death. Oncology. 2015;88:28-48 pubmed publisher

Chang T, Mikheev A, Huynh W, Monnat R, Rostomily R, Folch A. Parallel microfluidic chemosensitivity testing on individual slice cultures. Lab Chip. 2014;14:4540-51 pubmed publisher

Vo V, Lee J, Lee H, Chun W, Lim S, Kim S. Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation. Anticancer Res. 2014;34:5509-15 pubmed

Miki Y, Akimoto J, Omata H, Moritake K, Hiranuma M, Hironaka C, et al. Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium. Photodiagnosis Photodyn Ther. 2014;11:556-64 pubmed publisher

Jotte R, Von Hoff D, Braiteh F, Becerra C, Richards D, Smith D, et al. An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. Invest New Drugs. 2015;33:148-58 pubmed publisher

Wu L, Yang L, Xiong Y, Guo H, Shen X, Cheng Z, et al. Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells. Tumour Biol. 2014;35:12327-37 pubmed publisher

Singh Y, Ojha P, Srivastava M, Chourasia M. Reinvestigating nanoprecipitation via Box-Behnken design: a systematic approach. J Microencapsul. 2015;32:75-85 pubmed publisher

Redjal N, Zhu Y, Shah K. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells. 2015;33:101-10 pubmed publisher

Brandwein J, Kassis J, Leber B, Hogge D, Howson Jan K, Minden M, et al. Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression. Br J Haematol. 2014;167:664-70 pubmed publisher

Herzog S, Fink M, Weitmann K, Friedel C, Hadlich S, Langner S, et al. Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival. Neuro Oncol. 2015;17:223-42 pubmed publisher

Nonnenmacher L, Westhoff M, Fulda S, Karpel Massler G, Halatsch M, Engelke J, et al. RIST: a potent new combination therapy for glioblastoma. Int J Cancer. 2015;136:E173-87 pubmed publisher

Fukai J, Koizumi F, Nakao N. Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase. PLoS ONE. 2014;9:e104538 pubmed publisher

Tanaka S, Akimoto J, Narita Y, Oka H, Tashiro T. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?. J Neurosurg. 2014;121:818-26 pubmed publisher

Jiang G, Sun C, Li R, Wei Z, Zheng J, Liu Y. Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo. J Cancer Res Clin Oncol. 2015;141:75-85 pubmed publisher

Agnihotri S, Burrell K, Buczkowicz P, Remke M, Golbourn B, Chornenkyy Y, et al. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov. 2014;4:1198-213 pubmed publisher

Roix J, Harrison S, Rainbolt E, Meshaw K, McMurry A, Cheung P, et al. Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity. PLoS ONE. 2014;9:e101708 pubmed publisher

Wojciechowicz K, Cantelli E, Van Gerwen B, Plug M, van der Wal A, Delzenne Goette E, et al. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome. Gastroenterology. 2014;147:1064-72.e5 pubmed publisher

Lan J, Xue Y, Chen H, Zhao S, Wu Z, Fang J, et al. Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis. FEBS Lett. 2014;588:3333-9 pubmed publisher

Nguyen S, Stechishin O, Luchman H, Lun X, Senger D, Robbins S, et al. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Clin Cancer Res. 2014;20:4894-903 pubmed publisher

Ferolla P. Medical treatment of advanced thoracic neuroendocrine tumors. Thorac Surg Clin. 2014;24:351-5 pubmed publisher

Munoz J, Rodriguez Cruz V, Greco S, Nagula V, Scotto K, Rameshwar P. Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells. Mol Cancer Ther. 2014;13:2399-411 pubmed publisher

Desai A, Gerson S. Exo1 independent DNA mismatch repair involves multiple compensatory nucleases. DNA Repair (Amst). 2014;21:55-64 pubmed publisher

Cho H, Wang W, Jhaveri N, Lee D, Sharma N, Dubeau L, et al. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. Mol Cancer Ther. 2014;13:2004-17 pubmed publisher

Rangwala R, Leone R, Chang Y, Fecher L, Schuchter L, Kramer A, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014;10:1369-79 pubmed publisher

Rosen D, Leung L, Louie B, Cordeiro J, Conroy A, Shapira I, et al. Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP). J Transl Med. 2014;12:184 pubmed publisher

Quadrato G, Elnaggar M, Duman C, Sabino A, Forsberg K, Di Giovanni S. Modulation of GABAA receptor signaling increases neurogenesis and suppresses anxiety through NFATc4. J Neurosci. 2014;34:8630-45 pubmed publisher

Carvajal R, Sosman J, Quevedo J, Milhem M, Joshua A, Kudchadkar R, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311:2397-405 pubmed publisher

Goldwirt L, Beccaria K, Carpentier A, Farinotti R, Fernandez C. Irinotecan and temozolomide brain distribution: a focus on ABCB1. Cancer Chemother Pharmacol. 2014;74:185-93 pubmed publisher

Shi Z, Chen Q, Li C, Wang L, Qian X, Jiang C, et al. MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neuro Oncol. 2014;16:1341-53 pubmed publisher

Muñoz Gámez J, López Viota J, Barrientos A, Carazo A, Sanjuan Nuñez L, Quiles Perez R, et al. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles. Liver Int. 2015;35:1430-41 pubmed publisher

Burrell K, Singh S, Jalali S, Hill R, Zadeh G. VEGF regulates region-specific localization of perivascular bone marrow-derived cells in glioblastoma. Cancer Res. 2014;74:3727-39 pubmed publisher

Wilisch Neumann A, Pachow D, Wallesch M, Petermann A, Bohmer F, Kirches E, et al. Re-evaluation of cytostatic therapies for meningiomas in vitro. J Cancer Res Clin Oncol. 2014;140:1343-52 pubmed publisher

Berthois Y, Delfino C, Metellus P, Fina F, Nanni Metellus I, Al Aswy H, et al. Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O?-methylguanine methyltransferase and promotes temozolomide responsiveness. Cancer Biol Ther. 2014;15:938-50 pubmed publisher

Hadoux J, Favier J, Scoazec J, Leboulleux S, Al Ghuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014;135:2711-20 pubmed publisher

Olson J, Nayak L, Ormond D, Wen P, Kalkanis S. The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014;118:501-55 pubmed publisher

Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer H, Stockhammer G, et al. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology. 2014;82:1684-92 pubmed publisher

Palumbo S, Tini P, Toscano M, Allavena G, Angeletti F, Manai F, et al. Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells. J Cell Physiol. 2014;229:1863-73 pubmed publisher

Murai J, Zhang Y, Morris J, JI J, Takeda S, Doroshow J, et al. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther. 2014;349:408-16 pubmed publisher

Turley R, Tokuhisa Y, Toshimitsu H, Lidsky M, Padussis J, Fontanella A, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015;261:368-77 pubmed publisher

Muller K, Schlamann A, Guckenberger M, Warmuth Metz M, Gluck A, Pietschmann S, et al. Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group. Strahlenther Onkol. 2014;190:377-81 pubmed publisher

Palmieri D, Duchnowska R, Woditschka S, Hua E, Qian Y, Biernat W, et al. Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clin Cancer Res. 2014;20:2727-39 pubmed publisher

Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer. 2014;134:2437-47 pubmed

Fine H. Bevacizumab in glioblastoma--still much to learn. N Engl J Med. 2014;370:764-5 pubmed publisher

Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709-22 pubmed publisher

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699-708 pubmed publisher

Panosyan E, Wang Y, Xia P, Lee W, Pak Y, Laks D, et al. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors. Mol Cancer Res. 2014;12:694-702 pubmed publisher

Lipson E, Bodell M, Kraus E, Sharfman W. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32:e69-71 pubmed publisher

Becker F, Hecht M, Schmidtner J, Semrau S, Fietkau R. Temozolomide-induced liver damage. A case report. Strahlenther Onkol. 2014;190:408-10 pubmed publisher

Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol. 2014;170:R121-32 pubmed publisher

Bautista F, Paci A, Minard Colin V, Dufour C, Grill J, Lacroix L, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61:1101-3 pubmed publisher

Sha S, Wu H, Lu K, Chen H, Huang P, Huang S, et al. Extraneural metastases of anaplastic oligodendroglioma. APMIS. 2014;122:660-2 pubmed publisher

Takanen S, Bangrazi C, Caiazzo R, Raffetto N, Tombolini V. Multiple bone metastases from glioblastoma multiforme without local brain relapse: a case report and review of the literature. Tumori. 2013;99:e237-40 pubmed publisher

Kaloshi G, Brace G, Rroji A, Bushati T, Roci E, Hoxha M, et al. Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience. Tumori. 2013;99:601-3 pubmed publisher

Li L, Puliyappadamba V, Chakraborty S, Rehman A, Vemireddy V, Saha D, et al. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. Oncogene. 2015;34:129-134 pubmed publisher

Johnson B, Mazor T, Hong C, Barnes M, Aihara K, McLean C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343:189-193 pubmed publisher

Yang L, Zhou C, Lin Z. Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. Cancer Invest. 2014;32:31-6 pubmed publisher

Kim S, Jo S, Lee H, Kim T, Kim I, Yim J, et al. Lobarstin enhances chemosensitivity in human glioblastoma T98G cells. Anticancer Res. 2013;33:5445-51 pubmed

Tang L, Guérard M, Zeller A. Quantitative assessment of the dose-response of alkylating agents in DNA repair proficient and deficient ames tester strains. Environ Mol Mutagen. 2014;55:15-23 pubmed publisher

Armstrong A, Dargart J, Reichek J, Walterhouse D, Matossian D, Cohn R, et al. Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. Pediatr Blood Cancer. 2014;61:949-50 pubmed publisher

Juratli T, Engellandt K, Lautenschlaeger T, Geiger K, von Kummer R, Cerhova J, et al. Is there pseudoprogression in secondary glioblastomas?. Int J Radiat Oncol Biol Phys. 2013;87:1094-9 pubmed publisher

Bagatell R, Norris R, Ingle A, Ahern C, Voss S, Fox E, et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr Blood Cancer. 2014;61:833-9 pubmed publisher

Batchelor T, Gerstner E, Emblem K, Duda D, Kalpathy Cramer J, Snuderl M, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013;110:19059-64 pubmed publisher

Fan C, Liu W, Cao H, Wen C, Chen L, Jiang G. O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis. 2013;4:e876 pubmed publisher

Alnaami I, Al Nuaimi S, Senthilselvan A, Murtha A, Walling S, Mehta V, et al. Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma. Neurosciences (Riyadh). 2013;18:349-55 pubmed

Polley M, Freidlin B, Korn E, Conley B, Abrams J, McShane L. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst. 2013;105:1677-83 pubmed publisher

Jakubowicz Gil J, Langner E, Badziul D, Wertel I, Rzeski W. Silencing of Hsp27 and Hsp72 in glioma cells as a tool for programmed cell death induction upon temozolomide and quercetin treatment. Toxicol Appl Pharmacol. 2013;273:580-9 pubmed publisher

Venkatramani R, Malogolowkin M, Mascarenhas L. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr Blood Cancer. 2014;61:756-9 pubmed publisher

Kim S, Seong S, Lim S, Kim S. Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma. Biochem Biophys Res Commun. 2013;440:658-63 pubmed publisher

Armstrong T, Wefel J, Wang M, Gilbert M, Won M, Bottomley A, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013;31:4076-84 pubmed publisher

Wang M, Aldape K, Stupp R, Hegi M, Jaeckle K, Armstrong T, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31:4085-91 pubmed publisher

Bota D, Alexandru D, Keir S, Bigner D, Vredenburgh J, Friedman H. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. J Neurosurg. 2013;119:1415-23 pubmed publisher

Eisele G, Wolpert F, Decrey G, Weller M. APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells. Anticancer Res. 2013;33:3563-71 pubmed

Bailey S, Howman A, Wheatley K, Wherton D, Boota N, Pizer B, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer. 2013;49:3856-62 pubmed publisher

Tsen A, Long P, Driscoll H, Davies M, Teasdale B, Penar P, et al. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. Int J Cancer. 2014;134:1300-10 pubmed publisher

Balducci M, Fiorentino A, De Bonis P, Chiesa S, Mangiola A, Mattiucci G, et al. Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. Strahlenther Onkol. 2013;189:926-31 pubmed publisher

Faje A, Nachtigall L, Wexler D, Miller K, Klibanski A, Makimura H. Central diabetes insipidus: a previously unreported side effect of temozolomide. J Clin Endocrinol Metab. 2013;98:3926-31 pubmed publisher

Tobias A, Thaci B, Auffinger B, Rincón E, Balyasnikova I, Kim C, et al. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl Med. 2013;2:655-66 pubmed publisher

Scaringi C, De Sanctis V, Minniti G, Enrici R. Temozolomide-related hematologic toxicity. Onkologie. 2013;36:444-9 pubmed publisher

Wang Y, Liu B, Xu D, Zhao H, Zhu Y, Xu J, et al. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma. Neurol India. 2013;61:260-4 pubmed publisher

Lee D, Chunta J, Park S, Huang J, Martinez A, Grills I, et al. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2013;86:978-85 pubmed publisher

Anderson M, Gilbert M. Treatment recommendations for anaplastic oligodendrogliomas that are codeleted. Oncology (Williston Park). 2013;27:315-20, 322 pubmed

Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013;60:1621-5 pubmed publisher

Mullins C, Schubert J, Schneider B, Linnebacher M, Classen C. Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers. J Cancer Res Clin Oncol. 2013;139:1425-31 pubmed publisher

Lukas R, Vigneswaran J, Salgia R. Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases. Tumori. 2013;99:e73-6 pubmed publisher

St Coeur P, Touaibia M, Cuperlovic Culf M, Morin P. Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas. Genomics Proteomics Bioinformatics. 2013;11:199-206 pubmed publisher

Chinnaiyan P, Won M, Wen P, Rojiani A, Wendland M, DiPetrillo T, et al. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2013;86:880-4 pubmed publisher

Clark S, Taylor J, Wang D, Abramson J, Batchelor T. Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma. Neurology. 2013;81:93-4 pubmed publisher

Szczepanek D, Marchel A, Moskała M, Krupa M, Kunert P, Trojanowski T. Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized study. Neurol Neurochir Pol. 2013;47:101-8 pubmed

Grossman R, Tyler B, Rudek M, Kim E, Zadnik P, Khan U, et al. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. Cancer Chemother Pharmacol. 2013;72:93-100 pubmed publisher

Josset E, Burckel H, Noel G, Bischoff P. The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. Anticancer Res. 2013;33:1845-51 pubmed

Wang J, Sai K, Chen F, Chen Z. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol. 2013;72:147-58 pubmed publisher

Minniti G, Scaringi C, Baldoni A, Lanzetta G, De Sanctis V, Esposito V, et al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. Int J Radiat Oncol Biol Phys. 2013;86:285-91 pubmed publisher

Hart M, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2013;:CD007415 pubmed publisher

Wagner L, Turpin B, Nagarajan R, Weiss B, CRIPE T, Geller J. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatr Blood Cancer. 2013;60:1447-51 pubmed publisher

Ekblad T, Camaioni E, Schüler H, Macchiarulo A. PARP inhibitors: polypharmacology versus selective inhibition. FEBS J. 2013;280:3563-75 pubmed publisher

Sanchez Perez L, Choi B, Reap E, Sayour E, Norberg P, Schmittling R, et al. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother. 2013;62:983-7 pubmed publisher

Costa F, Gumz B, Pasche B. Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:843-54 pubmed publisher

Hummel T, Wagner L, Ahern C, Fouladi M, Reid J, McGovern R, et al. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013;60:1452-7 pubmed publisher

Kruser T, Mehta M, Robins H. Pseudoprogression after glioma therapy: a comprehensive review. Expert Rev Neurother. 2013;13:389-403 pubmed publisher

Yeo K, Puscasiu E, Keating R, Rood B. Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide. J Neurosurg Pediatr. 2013;11:682-6 pubmed publisher

Chen L, Guerrero Cazares H, Ye X, Ford E, McNutt T, Kleinberg L, et al. Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection. Int J Radiat Oncol Biol Phys. 2013;86:616-22 pubmed publisher

Gutenberg A, Lumenta C, Braunsdorf W, Sabel M, Mehdorn H, Westphal M, et al. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol. 2013;113:163-74 pubmed publisher

Barker C, Bishop A, Chang M, Beal K, Chan T. Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys. 2013;86:504-9 pubmed publisher

Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, et al. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Tumour Biol. 2013;34:1935-47 pubmed publisher

Chu S, Ma Y, Feng D, Li Z, Jiang P. Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy. J Transl Med. 2013;11:69 pubmed publisher

Kohsaka S, Kanno H, Tanaka S. [Regulation of MGMT and application for the therapy to attenuate the chemoresistance]. Nihon Rinsho. 2012;70 Suppl 8:346-52 pubmed

Grah J, Katalinic D, Stern Padovan R, Paladino J, Santek F, Juretic A, et al. Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy. World J Surg Oncol. 2013;11:55 pubmed publisher

Janco J, Markovic S, Weaver A, Cliby W. Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy. Gynecol Oncol. 2013;129:533-7 pubmed publisher

Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol P, et al. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Invest. 2013;31:190-6 pubmed publisher

Markiewicz Żukowska R, Borawska M, Fiedorowicz A, Naliwajko S, Sawicka D, Car H. Propolis changes the anticancer activity of temozolomide in U87MG human glioblastoma cell line. BMC Complement Altern Med. 2013;13:50 pubmed publisher

Jiang G, Jiang A, Cheng Q, Tian H, Li L, Zheng J. A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis. Tumour Biol. 2013;34:1263-71 pubmed publisher

Marcus D, Lowe M, Khan M, Lawson D, Crocker I, Shelton J, et al. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am J Clin Oncol. 2014;37:580-4 pubmed publisher

Friedman G, Spiller S, Harrison D, Fiveash J, Reddy A. Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection. J Pediatr Hematol Oncol. 2013;35:e123-6 pubmed publisher

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, et al. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Radiat Oncol. 2013;8:38 pubmed publisher

Plummer R, Lorigan P, Steven N, Scott L, Middleton M, Wilson R, et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol. 2013;71:1191-9 pubmed publisher

Nelson B. Targeting a murky cancer reservoir: more researchers set their sights on cancer stem cells. Cancer Cytopathol. 2013;121:55-6 pubmed publisher

Poteet E, Choudhury G, Winters A, Li W, Ryou M, Liu R, et al. Reversing the Warburg effect as a treatment for glioblastoma. J Biol Chem. 2013;288:9153-64 pubmed publisher

Fiorentino A, Balducci M, De Bonis P, Chiesa S, De Filippo L, Mangiola A, et al. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?. Am J Clin Oncol. 2015;38:23-7 pubmed publisher

Jeyapalan S, Boxerman J, Donahue J, Goldman M, Kinsella T, DiPetrillo T, et al. Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study. Am J Clin Oncol. 2014;37:444-9 pubmed publisher

Hirst T, Vesterinen H, Sena E, Egan K, Macleod M, Whittle I. Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?. Br J Cancer. 2013;108:64-71 pubmed publisher

Grant L, Kleiner D, Conjeevaram H, Vuppalanchi R, Lee W. Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide. Dig Dis Sci. 2013;58:1415-21 pubmed publisher

Sengupta S, Marrinan J, Frishman C, Sampath P. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol. 2012;2012:831090 pubmed publisher

Zhang N, Wu X, Yang L, Xiao F, Zhang H, Zhou A, et al. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res. 2012;18:5961-71 pubmed publisher

De Vos F, Gijtenbeek J, Bleeker Rovers C, van Herpen C. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Crit Rev Oncol Hematol. 2013;85:373-82 pubmed publisher

Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs. 2012;23:1099-106 pubmed

Scorsetti M, Alongi F, Clerici E, Navarria P, Simonelli M, Rognone E, et al. Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. Tumori. 2012;98:67e-71e pubmed publisher

Tatar Z, Thivat E, Planchat E, Gimbergues P, Gadéa E, Abrial C, et al. Temozolomide and unusual indications: review of literature. Cancer Treat Rev. 2013;39:125-35 pubmed publisher

Jiang G, Li L, Xin Y, Zhang L, Liu Y, Zheng J. Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT. Curr Med Chem. 2012;19:3886-92 pubmed

Chen C, Xu T, Lu Y, Chen J, Wu S. The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol. 2013;20:223-30 pubmed publisher

Johannessen T, Bjerkvig R. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther. 2012;12:635-42 pubmed publisher

Ortiz L, Syro L, Scheithauer B, Rotondo F, Uribe H, Fadul C, et al. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo). 2012;67 Suppl 1:119-23 pubmed

Nagasawa D, Chow F, Yew A, Kim W, Cremer N, Yang I. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am. 2012;23:307-22, ix pubmed publisher

Strik H, Marosi C, Kaina B, Neyns B. Temozolomide dosing regimens for glioma patients. Curr Neurol Neurosci Rep. 2012;12:286-93 pubmed publisher

Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella Branger D, Dufour H, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf). 2012;76:769-75 pubmed publisher

Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7:e1002310 pubmed publisher

Ekins S, Williams A, Xu J. A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug Metab Dispos. 2010;38:2302-8 pubmed publisher

Penning T, Zhu G, Gong J, Thomas S, Gandhi V, Liu X, et al. Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor. J Med Chem. 2010;53:3142-53 pubmed publisher

Toropov A, Toropova A, Raska I, Benfenati E. QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations. Eur J Med Chem. 2010;45:1639-47 pubmed publisher

Fourches D, Barnes J, Day N, Bradley P, Reed J, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol. 2010;23:171-83 pubmed publisher

Tong Y, Bouska J, Ellis P, Johnson E, Leverson J, Liu X, et al. Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents. J Med Chem. 2009;52:6803-13 pubmed publisher

Rhee H, Lim S, Jung M, Kwon Y, Kim M, Choo H. Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. Bioorg Med Chem. 2009;17:7537-41 pubmed publisher

Lena A, Rechichi M, Salvetti A, Bartoli B, Vecchio D, Scarcelli V, et al. Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells. J Transl Med. 2009;7:13 pubmed publisher

Penning T, Zhu G, Gandhi V, Gong J, Liu X, Shi Y, et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009;52:514-23 pubmed publisher

Menear K, Adcock C, Boulter R, Cockcroft X, Copsey L, Cranston A, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008;51:6581-91 pubmed publisher

Obach R, Lombardo F, Waters N. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36:1385-405 pubmed publisher

Pelletier D, Gehlhaar D, Tilloy Ellul A, Johnson T, Greene N. Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J Chem Inf Model. 2007;47:1196-205 pubmed

Kurzen H, Schmitt S, Näher H, Möhler T. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs. 2003;14:515-22 pubmed

Tentori L, Leonetti C, Scarsella M, D Amati G, Portarena I, Zupi G, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002;99:2241-4 pubmed

Hirose Y, Berger M, Pieper R. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001;61:1957-63 pubmed